INHIBITION of adrenal cortical function by compounds having a direct action on steroid biosynthesis has been most extensively studied in the case of the drug amphenone, synthesized by Allen and Corwin in 1950 . Several workers have demonstrated that adrenal steroid secretion could be reduced by this substance both in the dog and in man, but unfortunately the toxic effects of amphenone have precluded its widespread use, and have led to the search for further inhibitory agents.
Recently the compound 2-methyl-1-2-bis(3 pyridyl)-l-propanone, known as D.P.P. or S.U.4885, as it will be referred to in this paper, has been synthesized by Allen and Bencze (Chart -et al., 1958) , and the action of this drug on adrenal cortical secretion has been studied both in the dog and in man.
Experiments were carried out on normal dogs .anesthetized by sodium pentobarbitone. An intravenous infusion of ACTH was given to obviate any changes in adrenal stimulation. *The right lumbo-adrenal vein was cannulated and adrenal venous blood was collected at timed intervals. The plasma was separated and total 17-hydroxycorticoids were estimated by the Nelson and Samuels (1952) method. Individual steroids were characterized by paper chromatography, identification being carried out by a comparison of running rates of the free and acetylated substance with known standards in different chromatographic systems, ultraviolet light absorption, blue tetrazolium, and phenylhydrazine reactions, sulphuric acid absorption spectra and in some instances infra-red spectroscopy. Quantitative estimation was carried out by elution of the steroids off the paper and application of the phenylhydrazine or blue tetrazolium reactions.
A single intravenous injection of 75 mg. of S.U.4885 per kg. caused a fall in total 17hydroxycorticoids in the adrenal venous blood of the dog to approximately 10% of the initial values within ten minutes, rising to about 75% in three hours.
A smaller dose of 5 mg./kg., given intravenously over thirty minutes, produced no decrease in total 17-hydroxycorticoids. When the infusion was increased to 75 mg./kg. a reduction in steroid output was again observed.
The most striking effect of the drug, however, was seen when the individual plasma steroids were characterized.
After a single injection of 75 mg. of S.U.4885 per kg. hydrocortisone fell from 7 0 ,ug. per minute to immeasurable levels within ten minutes but even after seven hours the value was still only 0 9 jtg., returning to approximately initial levels by twenty hours. Concomitant with the prolonged inhibition of hydrocortisone was the appearance of 1-desoxyhydrocortisone, Reichstein's substance S, which rose from previously undetectable levels to 5-6 pg. five hours after the injection of the drug. Corticosterone, initially present in large amounts in the control sample, disappeared and was replaced by desoxycorticosterone.
When only 5 mg. of S.U.4885 per kg. was administered, hydrocortisone was again inhibited contrary to what would be expected from the total 17-hydroxycorticoid values, the major part of which was evidently due to substance S. Desoxycorticosterone also appeared once more in place of corticosterone. The infusion of 75 mg./kg. caused a temporary reduction in total steroid output but again the predominant component was substance S.
In view of these results it was of interest to compare the effect of amphenone on the steroid pattern when given in a dosage equivalent to 75 mg./kg. of S.U.4885. This caused a temporary reduction in hydrocortisone and corticosterone. During the following three hours the levels of both steroids gradually rose but without any evidence of 1 1-desoxy compounds.
Following these experiments carried out in the dog, it was important to study the action of S.U.4885 in man, bearing in mind that adrenal inhibitory agents sometimes show considerable species specificity. 8 patients were studied including 4 cases of Cushing's syndrome, and 4 who showed no evidence of adrenal abnormality. 5 of the patients received the drug intravenously.
2 grams of the drug was administered as an intravenous infusion over eight hours to a patient suffering from Cushing's syndrome. Tetrahydrocortisone (THE) and tetrahydrohydrocortisone (THF) were temporarily reduced but this was accompanied by the appearance of large quantities of tetrahydro-S (THS) previously
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reported by other workers to be a major urinary metabolite of substance S. Plasma free and conjugated corticosteroids were also studied in the same patient. In this case an eight-hour infusion of ACTH was given and a blood sample taken at the end of four hours. 2 grams of S.U.4885 was then administered intravenously over a further four hours and at the end of this period there was a reduction in both hydrocortisone and tetrahydrohydrocortisone with the appearance of substance S and very large quantities of tetrahydro-S. 3 patients were given S.U.4885 orally in amounts ranging from 3-12 grams daily, divided into four-hourly doses. In every case total urinary 17-hydroxycorticoids increased considerably following administration of the drug and remained elevated above the control values up to two days after it was discontinued. Urinary 1 7-ketosteroids were also elevated. The 17-hydroxycorticoids include THE, THF and THS. In a patient receiving 3-6 grams of the drug there was a great increase in the excretion of THS but THE and THF remained essentially unchanged. It appears that this dosage orally only partially inhibits 1 1-hydroxylation and it would seem that any tendency for hydrocortisone to fall would be followed by increased output of ACTH, thereby restoring to normal the levels of hydrocortisone and its urinary metabolites, but stimulating still further the production of substance S, and also elevating 17-ketosteroid excretion.
When, however, 6-12 grams of the drug was given to a patient, this was sufficient to inhibit 1 l-hydroxylation more intensively and a marked fall in THE and THF was observed, the output of THS rising to 28 5 mg. per twenty-four hours. The elevated levels of 17-hydroxycorticoids seen in all cases was therefore due to the large amounts of THS excreted. The urine of 2 patients was also examined for evidence of tetrahydrodesoxycorticosterone (THDOC), a urinary metabolite of desoxycorticosterone. In both cases a substance was identified which behaved chromatographically and spectrophotometrically in a similar manner to that reported for authentic tetrahydrodesoxycorticosterone. Quantitative determination yielded values which rose from initially undetectable levels to a maximum of 0-9 mg. per twenty-four hours in one case, and 0-7 mg. in the other, whilst receiving the drug.
Toxic effects were much less prominent with S.U.4885 than with amphenone. No untoward effects were seen in any of the patients receiving the drug intravenously. Nausea and gastric discomfort, however, were experienced by all patients taking 6 grams or more orally. This was partly controlled by giving aluminium hydroxide. Dizziness was complained of by a patient taking 12 grams daily, but drowsiness, which is such a prominent feature with amphenone therapy, was not seen in any patient.
In conclusion, S.U.4885, when given in large doses to the dog, caused a fall in total adrenal corticosteroid secretion, but this was of relatively short duration and was followed by a prolonged period during which 11 p-hydroxylation alone was inhibited and substance S and desoxycorticosterone were secreted. In the relatively smaller doses administered to the patients no fall in total steroids was seen, but the large quantities of 11 -desoxy compounds present in blood and urine again indicated that the inhibitory action of this drug is directed particularly at the llB-hydroxylase enzyme system. In this respect the action of S.U.4885 differs considerably from that of amphenone, which causes a generalized inhibition of steroid synthesis with no selective effect on 11 ,Bhydroxylation. The effect of S.U.4885 is in fact comparable with the congenital failure of 11 p-hydroxylation described by Eberlein and Bongiovanni (1956) in some cases of adrenal hyperplasia. These patients also excrete large quantities of THS and also THDOC, which may perhaps be a factor in the hypertension seen in this type of congenital adrenal hyperplasia. None of the patients receiving S.U.4885 showed any change in blood pressure, but this may have been due to the relatively short period of administration since THDOC was tentatively identified in the urine of 2 cases. From these considerations it would not appear that S.U.4885 has an immediate clinical application. Nevertheless, selective inhibition of an adrenal enzyme system is of considerable interest, although the exact mode of action remains to be elucidated. It seems probable that further compounds will be elaborated, the study of which may lead to increased knowledge of the mechanisms of adrenal steroid biosynthesis.
(A more detailed paper relating to this subject will appear in the British Medical Journal.)
